Freeline_Logo_Red_RGB.jpg
Freeline Announces Expansion of Executive Leadership
February 16, 2021 07:00 ET | Freeline Therapeutics
Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments Chief Financial Officer Brian M. Silver leaving...
Freeline_Logo_Red_RGB.jpg
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
February 08, 2021 16:01 ET | Freeline Therapeutics
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease ...
Freeline_Logo_Red_RGB.jpg
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program
February 08, 2021 07:00 ET | Freeline Therapeutics
Targeting initiation of dose confirmation trial by end of 2021 with data readout by end of 2022 Initiation of Phase 3 pivotal trial targeted by mid-2023, with data readout and BLA filing targeted by...
Freeline_Logo_Red_RGB.jpg
Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
January 26, 2021 07:00 ET | Freeline Therapeutics
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline to participate at Conferences during January 2021
January 04, 2021 07:00 ET | Freeline Therapeutics
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
December 14, 2020 07:00 ET | Freeline Therapeutics
Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with...
Freeline_Logo_Red_RGB.jpg
Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference
November 19, 2020 07:00 ET | Freeline Therapeutics
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline appoints Mark Baldry as Chief Commercial Officer
November 02, 2020 07:00 ET | Freeline Therapeutics
LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline_Logo_Red_RGB.jpg
Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit
October 30, 2020 07:00 ET | Freeline Therapeutics
- Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes - Potentially increasing safety and efficacy in Freeline’s AAV delivery...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights
October 29, 2020 16:15 ET | Freeline Therapeutics
Will report updated durability data from Phase 1/2 B-AMAZE trial in Haemophilia B in Q4 Third wholly-owned programme expected to be in the clinic in 2021 Strong cash position with over $250 million...